The role of clinical imaging in oncological drug development

British Journal of Radiology

Volumn 81, Issue 969, 2008, Pages 685-692

  Murphy, Philip S ^a,d   McCarthy, T J ^b   Dzik Jurasz, A S K ^c  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3' DEOXY 3' FLUOROTHYMIDINE F 18; ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; BIOLOGICAL MARKER; CONTRAST MEDIUM; FLUORODEOXYGLUCOSE F 18; IMATINIB; TRACER; UNCLASSIFIED DRUG;

BREAST CANCER; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DECISION MAKING; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG PENETRATION; GASTROINTESTINAL STROMAL TUMOR; HUMAN; IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOLOGY; POSITRON EMISSION TOMOGRAPHY; REVIEW; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CHEMISTRY, PHARMACEUTICAL; CLINICAL TRIALS AS TOPIC; DECISION MAKING; DIAGNOSTIC IMAGING; DRUG EVALUATION, PRECLINICAL; DRUG INDUSTRY; HUMANS; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; REPRODUCIBILITY OF RESULTS; TECHNOLOGY, PHARMACEUTICAL;

EID: 51349157100     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr/16768437     Document Type: Review

References (68)

1. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3:711-5.
2. Booth B, Zemmel R. Prospects for productivity. Nat Rev Drug Discov 2004;3:451-6.
3. Rudin M, Weissleder R. Molecular imaging in drug discovery and development. Nat Rev Drug Discov 2003;2:123-31.
4. Stahl A, Wieder H, Piert M, Wester HJ, Senekowitsch-Schmidtke R, Schwaiger M. Positron emission tomography as a tool for translational research in oncology. Mol Imaging Biol 2004;6:214-24.
5. Wilding IR, Bell JA. Improved early clinical development through human microdosing studies. Drug Discov Today 2005;10:890-4.
6. Kummar S, Kinders R, Rubinstein L, Parchment RE, Murgo AJ, Collins J, et al. Compressing drug development time-lines in oncology using phase '0' trials. Nat Rev Cancer 2007;7:131-9.
7. Garner RC, Lappin G. Commentary: the phase 0 microdosing concept. Br J Clin Pharmacol 2006;61:367-70.
8. Bergstrom M, Grahnen A, Langstrom B. Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development. Eur J Clin Pharmacol 2003;59:357-66.
9. Aboagye EO, Luthra SK, Brady F, Poole K, Anderson H, Jones T, et al. Cancer Research UK procedures in manufacture and toxicology of radiotracers intended for pre-phase I positron emission tomography studies in cancer patients. Br J Cancer 2002;86:1052-6.
10. Kairemo KJ, Tähtinen M. Radiolabeled compounds in the development of cytotoxic agents. Curr Pharm Des 2004;10:2923-34.
11. Hammond LA, Denis L, Salman U, Jerabek P, Thomas CR Jr, Kuhn JG. Positron emission tomography (PET): expanding the horizons of oncology drug development. Invest New Drugs 2003;21:309-40.
12. Roberts TG Jr, Goulart BH, Squitieri L, Stallings SC, Halpern EF, Chabner BA, et al. Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. JAMA 2004;292:2130-40.
13. Liu G, Rugo HS, Wilding G, McShane TM, Evelhoch JL, Ng C, et al. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. J Clin Oncol 2005;23:5464-73.
14. Morgan B, Thomas AL, Drevs J, Hennig J, Buchert M, Jivan A, et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 2003;21:3955-64.
15. Stevenson JP, Rosen M, Sun W, Gallagher M, Haller DG, Vaughn D, et al. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 2003;21:4428-38.
16. Mross K, Drevs J, Muller M, Medinger M, Marme D, Hennig J, et al. Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours. Eur J Cancer 2005;41:1291-9.
17. Thomas AL, Morgan B, Horsfield MA, Higginson A, Kay A, Lee L, et al. Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. J Clin Oncol 2005;23:4162-71.
18. Rehman S, Jayson GC. Molecular imaging of antiangiogenic agents. Oncologist 2005;10:92-103.
19. Jayson G, Waterton JC. Applications of dynamic contrast-enhanced MRI in oncology drug development. In: Jackson A, Parker GJM, Buckley DL, editors. Dynamic contrast-enhanced magnetic resonance imaging in oncology. Berlin: Springer-Verlag, 2005:281-97.
20. Jackson A, O'Connor JP, Parker GJ, Jayson GC. Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging. Clin Cancer Res 2007;13:3449-59.
21. O'Connor JP, Jackson A, Parker GJ, Jayson GC. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer 2007;96:189-95.
22. Tropres I, Grimault S, Vaeth A, Grillon E, Julien C, Payen JF, et al. Vessel size imaging. Magn Reson Med 2001;45:397-408.
23. Dennie J, Mandeville JB, Boxerman JL, Packard SD, Rosen BR, Weisskoff RM. NMR imaging of changes in vascular morphology due to tumor angiogenesis. Magn Reson Med 1998;40:793-99.
24. Taylor NJ, Baddeley H, Goodchild KA, Powell ME, Thoumine M, Culver LA, et al. BOLD MRI of human tumor oxygenation during carbogen breathing. J Magn Reson Imaging 2001;14:156-63.
25. Jayson GC, Parker GJM, Mullamitha S, Valle JW, Saunders M, Broughton L, et al. Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab′, leads to fluid accumulation and is associated with increased tumor vascularized volume. J Clin Oncol 2005;23:973-81.
26. Wedam SB, Low JA, Yang SX, Chow CK, Choyke P, Danforth D, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 2006;24:769-77.
27. Kelloff GJ, Hoffman JM, Johnson B, Scher HI, Siegel BA, Cheng EY, et al. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res 2005;11:2785-808.
28. Stroobants S, Goeminne J, Seegers M, Dimitrijevic S, Dupont P, Nuyts J, et al. 18FDG-positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 2003;39:2012-20.
29. Shields AF. PET imaging with 18F-FLT and thymidine analogs: promise and pitfalls. J Nucl Med 2003;44:1432-4.
30. Wells P, West C, Jones T, Harris A, Price P. Measuring tumor pharmacodynamic response using PET proliferation probes: the case for 2-[(11)C]-thymidine. Biochim Biophy Acta 2004;2:91-102.
31. Czernin J, Weber WA, Herschman HR. Molecular imaging in the development of cancer therapeutics. Annu Rev Med 2006;57:99-118.
32. Kelloff GJ, Krohn KA, Larson SM, Weissleder R, Mankoff DA, Hoffman JM, et al. The progress and promise of molecular imaging probes in oncologic drug development. Clin Cancer Res 2005;11:7967-85.
33. Van Den Bossche B, Van de Wiele C. Receptor imaging in oncology by means of nuclear medicine: current status. J Clin Oncol 2004;22:3593-607.
34. Weber WA. Chaperoning drug development with PET. J Nucl Med 2006;47:735-7.
35. Weber WA. Positron emission tomography as an imaging biomarker. J Clin Oncol 2006;24:3282-92.
36. Chenevert TL, Stegman LD, Taylor JM, Robertson PL, Greenberg HS, Rehemtulla A, et al. Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst 2000;92:2029-36.
37. Chenevert TL, Meyer CR, Moffat BA, Rehemtulla A, Mukherji SK, Gebarski SS, et al. Diffusion MRI: a new strategy for assessment of cancer therapeutic efficacy. Mol Imaging 2002;1:336-43.
38. Dzik-Jurasz A, Domenig C, George M, Wolber J, Padhani A, Brown G, et al. Diffusion MRI for prediction of response of rectal cancer to chemoradiation. Lancet 2002;360:307-8.
39. Mardor Y, Roth Y, Lidar Z, Jonas T, Pfeffer R, Maier SE, et al. Monitoring response to convection-enhanced taxol delivery in brain tumor patients using diffusion-weighted magnetic resonance imaging. Cancer Res 2001;61:4971-3.
40. Chinnaiyan AM, Prasad U, Shankar S, Hamstra DA, Shanaiah M, Chenevert TL, et al. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc Natl Acad Sci USA 2000;97:1754-9.
41. Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007;11:83-95.
42. Johnson JR, Williams G, Pazdur R. End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol 2003;21:1404-11.
43. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
44. Fuentes MA, Keith CJ, Griffiths M, Durbridge G, Miles KA. Hepatic haemodynamics: interrelationships between contrast enhancement and perfusion on CT and Doppler perfusion indices. Br J Radiol 2002;75:17-23.
45. Miles KA, GriffithsMR, Fuentes MA. Standardized perfusion value: universal ct contrast enhancement scale that correlates with FDG PET in lung nodules. Radiology 2001;220:548-53.
46. Parker GJ, Roberts C, Macdonald A, Buonaccorsi GA, Cheung S, Buckley DL, et al. Experimentally-derived functional form for a population-averaged high-temporal-resolution arterial input function for dynamic contrast-enhanced MRI. Magn Reson Med 2006;56:993-1000.
47. Roberts C, Issa B, Stone A, Jackson A, Waterton JC, Parker GJ. Comparative study into the robustness of compartmental modeling and model-free analysis in DCE-MRI studies. J Magn Reson Imaging 2006;23:554-63.
48. Weber WA, Schwaiger M, Avril N. Quantitative assessment of tumor metabolism using FDG-PET imaging. Nucl Med Biol 2000;27:683-7.
49. Jackson A, Haroon H, Zhu XP, Li KL, Thacker NA, Jayson G. Breath-hold perfusion and permeability mapping of hepatic malignancies using magnetic resonance imaging and a first-pass leakage profile model. NMR Biomed 2002;15:164-73.
50. Jackson A, Jayson GC, Li KL, Zhu XP, Checkley DR, Tessier JJ, et al. Reproducibility of quantitative dynamic contrast-enhanced MRI in newly presenting glioma. Br J Radiol 2003;76:153-62.
51. Testa AC, Mansueto D, Lorusso D, Fruscella E, Basso D, Scambia G, et al. Angiographic power 3-dimensional quantitative analysis in gynecologic solid tumors: feasibility and reproducibility. J Ultrasound Med 2004;23:821-8.
52. Alonso A, Molenberghs G, Geys H, Buyse M, Vangeneugden T. A unifying approach for surrogate marker validation based on Prentice's criteria. Stat Med 2006;25:205-21.
53. Boissel J-P, Collet J-P, Moleur P, Haugh M. Surrogate endpoints: a basis for a rational approach. Eur J Clin Pharmacol 1992;43:235-44.
54. Prentice R. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989;8:431-40.
55. Weir CJ, Walley RJ. Statistical evaluation of biomarkers as surrogate endpoints: a literature review. Stat Med 2006;25:183-203.
56. FDA Critical Path Initiative. US Food and Drug Administration. Available from: http://www.fda.gov/oc/initiatives/criticalpath [Accessed 30 April 2008].
57. Wagner JA, Williams SA, Webster CJ. Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs. Clin Pharmacol Ther 2007;81:104-7,
58. Williams SA, Slavin DE, Wagner JA, Webster CJ. A cost-effectiveness approach to the qualification and acceptance of biomarkers. Nat Rev Drug Discov 2006;5:897-902.
59. Pathak SD, Ng L, Wyman B, Fogarasi S, Racki S, Oelund JC, et al. Quantitative image analysis: software systems in drug development trials. Drug Discovery Today 2003;8:451-8.
60. Erasmus JJ, Gladish GW, Broemeling L, Sabloff BS, Truong MT, Herbst RS, et al. Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. J Clin Oncol 2003;21:2574-82.
61. Westerterp M, Pruim J, Oyen W, Hoekstra O, Paans A, Visser E, et al. Quantification of FDG PET studies using standardised uptake values in multi-centre trials: effects of image reconstruction, resolution and ROI definition parameters. Eur J Nucl Med Mol Imaging 2007;34:392-404.
62. Leach MO, Brindle KM, Evelhoch JL, Griffiths JR, Horsman MR, Jackson A, et al. Assessment of antiangiogenic and antivascular therapeutics using MRI: recommendations for appropriate methodology for clinical trials. Br J Radiol 2003;76:S87-91.
63. Evelhoch J, Garwood M, Vigneron D, Knopp M, Sullivan D, Menkens A, et al. Expanding the use of magnetic resonance in the assessment of tumor response to therapy: workshop report. Cancer Res 2005;65:7041-4.
64. Delbeke D, Coleman RE, Guiberteau MJ, Brown ML, Royal HD, Siegel BA, et al. Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. J Nucl Med 2006;47:885-95.
65. Laking GR, Price PM. On the development of rational standards for nuclear response evaluation. Q J Nucl Med 2003;47:3-7.
66. Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. Eur J Cancer 1999;35:1773-82.
67. Shankar LK, Hoffman JM, Bacharach S, Graham MM, Karp J, Lammertsma AA, et al. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute trials. J Nucl Med 2006;47:1059-66.
68. Farley J, Bast J, Birrer MJ. Biomarkers and clinical trial design. Gynecol Oncol 2006;103:3-5.